Immune Response and Risk of Serious Infection to SARS-Cov2

Study Overview
=================
Brief Summary
-----------------
To date, nearly 2 million people, including at least 100,000 in France, have been infected with SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2). This infection is very heterogeneous in nature, ranging from asymptomatic forms to acute respiratory distress syndrome patterns in 6.1% of cases, leading to an estimated overall mortality of 5.2%. Apart from age, few risk factors for a pejorative evolution have been identified: arterial hypertension, diabetes, cardiovascular history, obesity and chronic respiratory pathology in particular. The median incubation period is 5 days and the median time between the appearance of the first symptoms and the onset of hypoxia requiring admission to intensive care is 7 to 12 days. The mechanisms involved in the occurrence of these secondary worsening patterns are unclear. One hypothesis is that it is related to an inappropriate inflammatory response rather than a direct cytopathic effect of the virus. The objective of this study is to measure the intensity of the T lymphocyte response in patients hospitalized for Cov2 SARS infection in order to determine whether the intensity of the response is associated with worsening of symptoms.

Official Title
-----------------
Immune Response and Risk of Serious Infection to SARS-Cov2

Conditions
-----------------
SARS Cov2, Immune Response

Intervention / Treatment
-----------------
* Biological: Blood sample collection


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Person having given his or her non-opposition Patient hospitalized with an SARS-Cov2 infection proven by virological sampling (nasopharyngeal or sputum PCR) less than 8 days old. Exclusion Criteria: Person subject to a legal protection measure (curatorship, guardianship) Person subject to a safeguard measure of justice Pregnant, parturient or breastfeeding woman Major incapable or incapable of giving consent Minor

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patient<br>Patient hospitalized with SARS-Cov2 infection proven by virological sampling. | Biological: Blood sample collection<br>* Additional blood volumes taken during a routine care blood test: 1 dry tube 5 mL for isolation and freezing of serum 1 x 5 mL EDTA tube to isolate and freeze plasma 8 heparinized 6 mL tubes for flow cytometry study<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Percentage of circulating Th1 lymphocytes | Flow cytometry measurement of the percentage of circulating Th1 lymphocytes | Until the end of the study, about 12 months. | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Serum IFN concentrations-γ, CXCL9, CXCL10, CXCL11 | Immunofluorimetric measurement of serum concentrations of IFN-γ, CXCL9, CXCL10, CXCL11 | Until the end of the study, about 12 months. |